Long COVID has turned out to be one of the defining medical challenges of the 2020s — an estimated 65 million people worldwide are living with symptoms that persist weeks, months, or years after an acute COVID-19 infection. These aren't mild inconveniences. Cognitive impairment severe enough to prevent work. Fatigue that makes a short walk feel like a marathon. Breathlessness at rest. Pain that doesn't respond to standard treatments. A healthcare system that largely still doesn't know what to do with them.
HBOT has emerged as one of the more promising interventional approaches — not because it's trendy or because someone famous used it, but because a rigorous randomized controlled trial published in 2022 showed statistically significant, objective improvements in cognitive function, fatigue, sleep, and pain in long COVID patients. Brain imaging confirmed the effect. This is not anecdote or marketing. It's clinical trial data, and it deserves careful examination.
This article covers what long COVID is, why HBOT's mechanisms are particularly well-matched to its pathology, the key research (cited by study, author, and finding), and an honest assessment of what home chambers can and cannot offer in this context.
Medical context: Aimee is not a physician. This article is for educational purposes only. Long COVID is a complex medical condition requiring physician management. What follows is an explanation of the research — not medical advice for your specific situation. If you're considering HBOT for long COVID, that decision should involve your treating physician.
What Is Long COVID?
Long COVID — formally called post-acute sequelae of SARS-CoV-2, or PASC — is defined as symptoms persisting four or more weeks after a COVID-19 infection, without another explanation. The definition sounds simple. The condition is not.
By the WHO's estimate, approximately 10–30% of COVID-19 survivors develop some form of long COVID. With hundreds of millions of infections globally, that's an enormous patient population — roughly 65 million people, though estimates vary. The condition does not appear to track neatly with acute illness severity; many long COVID patients had mild or even asymptomatic initial infections.
What Makes It So Hard to Treat
Long COVID is not a single disease with a single mechanism. Research has identified multiple overlapping pathological processes, all contributing simultaneously:
- Microclotting and endothelial damage: COVID-19 causes widespread microvascular injury and persistent abnormal microclots that impair oxygen delivery at the tissue level — even after the virus itself has been cleared. This is tissue microhypoxia with normal blood oxygen readings.
- Neuroinflammation: Persistent inflammatory activation in the brain and peripheral nervous system — even without active viral presence — drives cognitive symptoms, fatigue, and autonomic dysfunction. PET imaging and cerebrospinal fluid analysis in long COVID patients show elevated inflammatory markers long after recovery.
- Mitochondrial dysfunction: COVID-19 appears to disrupt mitochondrial function in multiple tissues, reducing cellular energy production. This likely underlies the fatigue and post-exertional malaise that characterize long COVID — cells that can't make energy efficiently cannot support normal activity demands.
- Immune dysregulation: Persistent low-grade immune activation, possible viral reservoir persistence in gut and other tissues, and autoimmune-like responses against self-antigens have all been documented in long COVID patients.
- Autonomic nervous system disruption: Many long COVID patients develop dysautonomia — POTS (postural orthostatic tachycardia syndrome) and related conditions — representing dysfunction of the autonomic nervous system's control of heart rate, blood pressure, and other automatic functions.
Most treatments address one or two of these mechanisms at most. What makes HBOT particularly interesting for long COVID is that its mechanisms of action map directly onto three of the most important pathological drivers: microhypoxia, neuroinflammation, and mitochondrial dysfunction.
Why HBOT May Help: The Mechanisms
HBOT under pressure delivers oxygen dissolved in plasma at concentrations 10–13 times higher than normal breathing. This dissolved oxygen reaches tissues regardless of red blood cell access — which is directly relevant to the microclotting and endothelial dysfunction that impairs oxygen delivery in long COVID. But the mechanisms go well beyond simple oxygen delivery.
Reversing Tissue Microhypoxia
One of the core findings in long COVID pathology is that many tissues — including brain tissue — are chronically hypoxic despite normal pulse oximetry readings. The reason: the problem isn't getting oxygen into the blood, it's getting it out of the blood vessels and into the tissue, a process impaired by microvascular damage, microclotting, and endothelial dysfunction. Standard oxygen delivery through hemoglobin can't overcome this barrier.
HBOT bypasses this problem entirely. At 2.0–2.4 ATA with 100% oxygen, plasma oxygen content rises to levels where oxygen diffuses directly into tissue regardless of vascular compromise. This is the same mechanism that makes HBOT effective for diabetic foot ulcers and radiation injury — conditions where tissue microhypoxia is similarly driven by vascular dysfunction rather than inadequate systemic oxygenation.
Neuroinflammation Reduction
HBOT has well-documented anti-inflammatory effects that are particularly relevant to neurological manifestations of long COVID. Mechanically, HBOT suppresses key inflammatory mediators — TNF-α, IL-1β, and IL-6 — that drive neuroinflammation. It also promotes the resolution phase of inflammation rather than just suppressing the acute phase, which is important for a condition involving chronic, persistent inflammation rather than an acute inflammatory burst.
The neuroinflammation in long COVID shares significant overlap with the neuroinflammation seen in traumatic brain injury — the same microglial activation, the same disruption of blood-brain barrier integrity, the same patterns of impaired cerebral perfusion. HBOT has its strongest neurological evidence base in TBI, and it's this overlap that made researchers interested in applying it to long COVID's cognitive symptoms. The Brain Health & Neurological Recovery guide covers HBOT's neuroinflammation mechanisms in detail.
Mitochondrial Restoration
HBOT activates multiple mitochondrial repair pathways. It upregulates mitochondrial biogenesis (the production of new mitochondria), improves mitochondrial membrane potential, and enhances the efficiency of oxidative phosphorylation — the core process by which mitochondria convert oxygen into ATP. For long COVID patients whose fatigue and post-exertional malaise is driven by mitochondrial dysfunction, this mechanism is potentially transformative: it's not just delivering more oxygen, it's improving the cellular machinery that uses oxygen to generate energy.
This mitochondrial effect may explain why some long COVID patients report improvements in post-exertional malaise — the defining symptom where activity causes a disproportionate worsening of symptoms — that outlast the HBOT sessions themselves. Restored mitochondrial function persists after the treatment ends.
Angiogenesis and Cerebral Perfusion
As documented by Dr. Stephen Thom's stem cell mobilization research, HBOT drives neovascularization — the growth of new capillary networks — through CD34+ progenitor cell mobilization. In long COVID patients with microvascular damage in the brain, this angiogenic effect may help restore adequate blood flow to regions where perfusion has been compromised. The Zilberman-Itskovich 2022 trial's brain imaging data showing measurable improvement in cerebral perfusion is consistent with this mechanism.
Key Research: The Clinical Trial Evidence
The evidence base for HBOT in long COVID is younger than the wound healing literature — COVID-19 itself is only a few years old — but it's already more robust than most other interventions being tried for this condition.
Zilberman-Itskovich et al. 2022 — The Israeli RCT
This is the landmark study. Dr. Shai Efrati and colleagues (including lead author Dr. Sigal Zilberman-Itskovich) at the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Israel published this double-blind, randomized, sham-controlled trial in Scientific Reports in 2022.
73 long COVID patients with persistent cognitive symptoms were randomized to receive either HBOT (2.0 ATA, 100% oxygen, 90-minute sessions, 40 sessions over 8 weeks) or sham (1.2 ATA, normal air — below the threshold for meaningful physiological effect). The blinding was effective: patients couldn't reliably distinguish the groups during treatment.
The findings were striking:
- Cognitive function: Statistically significant improvement in attention, information processing speed, and executive function on standardized neuropsychological testing. The sham group showed no improvement.
- Fatigue: Significant reduction in fatigue scores on validated questionnaires (Multidimensional Fatigue Inventory) in the HBOT group vs. sham.
- Sleep quality: Significant improvement in sleep quality scores (Pittsburgh Sleep Quality Index) in the HBOT group.
- Pain: Significant reduction in widespread pain scores in the HBOT group.
- Brain imaging (MRI perfusion): Objective improvement in cerebral perfusion in specific brain regions (frontal lobe, temporal lobe, limbic system) associated with the cognitive and fatigue symptoms — confirming a biological mechanism, not just subjective reporting.
Why the imaging data matters: Subjective symptom scores can reflect placebo effect, particularly in a condition where patients are desperate for improvement. The MRI perfusion data in the Zilberman-Itskovich trial provides an objective biological correlate — the HBOT group showed measurable increases in brain blood flow in regions associated with their symptoms. This is hard to explain as placebo, and it aligns directly with HBOT's known angiogenic and microvascular mechanisms.
Belgian Pilot Study
A pilot study from Belgium (Vaes et al.) examined HBOT in long COVID patients with persistent symptoms. The study design was smaller and the protocol differed from the Israeli RCT — 10 sessions at 2.5 ATA — but results showed significant reductions in fatigue and improvements in quality of life measures in the treatment group. The pilot nature limits conclusions, but it independently supported the Israeli findings and contributed to the evidence base cited by physicians considering HBOT for long COVID patients.
Emerging 2024–2025 Data
Multiple clinical trials were underway as of 2025–2026, building on the Zilberman-Itskovich findings. Investigators in the United States, UK, Germany, and Australia have been running or completing randomized trials examining HBOT for long COVID with larger sample sizes and longer follow-up periods. Preliminary conference presentations and preprints from these studies have generally been consistent with the 2022 RCT results, though peer-reviewed publications are still forthcoming for most of these trials. The evidence trajectory is pointing in one direction: HBOT produces real, biologically measurable benefits in long COVID patients at clinical pressures. The open questions are around optimal protocol, patient selection, durability of benefit, and which symptom clusters respond most robustly.
| Study | Design | Protocol | Key Findings |
|---|---|---|---|
| Zilberman-Itskovich et al. 2022 RCT | Double-blind, sham-controlled; 73 patients | 40 sessions, 2.0 ATA, 90 min/session | Significant improvement: cognition, fatigue, sleep, pain + MRI perfusion |
| Vaes et al. (Belgian pilot) Pilot RCT | Randomized pilot; smaller N | 10 sessions, 2.5 ATA | Significant fatigue reduction, quality of life improvement |
| Multiple ongoing RCTs (2024–2026) In Progress | US, UK, Germany, Australia | Various; 2.0–2.4 ATA, 20–40 sessions | Preliminary data consistent with Zilberman-Itskovich; peer review pending |
Long COVID Symptoms HBOT Targets
The Zilberman-Itskovich 2022 trial documented improvements across four primary symptom domains. Understanding which symptoms map onto which mechanisms helps frame expectations realistically.
- Attention & concentration deficits
- Memory impairment
- Executive function decline
- Word-finding difficulties
- Mechanism: neuroinflammation + cerebral hypoperfusion
- Severe, disproportionate fatigue
- Worsening with minimal exertion
- Recovery time measured in days
- Mechanism: mitochondrial dysfunction + tissue hypoxia
- HBOT targets mitochondrial restoration
- Insomnia and unrefreshing sleep
- Circadian disruption
- Sleep fragmentation
- Mechanism: autonomic dysfunction + neuroinflammation
- Widespread musculoskeletal pain
- Headaches (often daily)
- Joint pain without inflammation on imaging
- Mechanism: neuroinflammation + central sensitization
Breathlessness and Cardiopulmonary Symptoms
Dyspnea — breathlessness at rest or with minimal exertion — is one of the most prevalent long COVID symptoms, reported by approximately 50–60% of long COVID patients in surveys. The RCT evidence base for HBOT specifically targeting breathlessness is thinner than for cognitive or fatigue symptoms. Observational and registry data suggest improvement in some patients, but breathlessness in long COVID has multiple potential causes (microclotting in pulmonary vasculature, autonomic dysfunction driving abnormal breathing patterns, genuine lung parenchymal damage) that HBOT addresses differentially. Breathlessness driven by pulmonary microclotting and tissue hypoxia is the subtype most mechanistically amenable to HBOT.
Autonomic Dysfunction (POTS/Dysautonomia)
POTS and broader dysautonomia are common in long COVID and can be among the most disabling manifestations. HBOT's effect on autonomic nervous system function in long COVID is an area of active investigation. The neuroinflammation-reduction mechanisms are relevant — autonomic dysfunction in long COVID appears partly driven by inflammatory damage to autonomic ganglia and the dorsal root ganglion. Some patients report improvement in POTS symptoms during HBOT courses, but dedicated RCT evidence for this symptom cluster specifically is still limited. Patients with POTS should work with their cardiologist or dysautonomia specialist when considering HBOT, as head-up positioning and pressure changes during sessions can affect heart rate and blood pressure.
Home vs. Clinical HBOT for Long COVID
The direct statement: home soft-shell chambers at 1.3 ATA are not a substitute for clinical HBOT for long COVID. The Zilberman-Itskovich RCT used 2.0 ATA. The Belgian pilot used 2.5 ATA. The clinical evidence for long COVID was established at pressures that home chambers cannot reach.
| Factor | Home 1.3 ATA | Clinical 2.0–2.4 ATA |
|---|---|---|
| RCT evidence for long COVID | None — trials used clinical pressures | Zilberman-Itskovich 2022 + Belgian pilot |
| Dissolved plasma oxygen | ~0.03 mL O₂/dL above breathing air | ~4.4–6.0 mL O₂/dL — 10–13× higher than air |
| Neuroinflammation reduction | Modest; dose-dependent effect | Documented in clinical trials at 2.0+ ATA |
| Mitochondrial activation | Possible mild effect at 1.3 ATA | Well-documented at clinical pressures |
| Cost per session | Low (after home chamber purchase) | $150–$350/session; 40-session course = $6,000–$14,000 |
| Accessibility | Daily at home, no scheduling | Clinical center required; 5 days/week for 8 weeks |
| Medical supervision | None (home use) | Physician monitoring throughout |
The Honest Case for Home Chambers in Long COVID
For long COVID patients who cannot access or afford clinical HBOT — and the 40-session clinical protocol at $150–$350/session represents a substantial financial barrier for most people — home chambers offer a pragmatic, if less evidence-supported, option.
1.3 ATA is not physiologically inert. It does increase dissolved plasma oxygen meaningfully compared to breathing air at sea level. It does have some anti-inflammatory effect. It does activate some mitochondrial response. The question is whether the dose is high enough to produce the clinical outcomes seen in the RCTs. We don't know — this specific question hasn't been studied.
What the evidence from other conditions suggests: 1.3 ATA produces measurable physiological effects, but those effects are substantially smaller than at 2.0–2.4 ATA. The dose-response relationship in HBOT is real and meaningful. For long COVID specifically, where the biological changes (microvascular damage, neuroinflammation) are significant, the lower pressure may not cross the threshold needed for the clinical benefits documented in the RCTs.
If you have access to clinical HBOT through a physician referral and your financial situation allows it, clinical HBOT at 2.0 ATA is what the evidence supports. Home chambers are an adjunct and a supplement, not a substitute. For mild residual post-COVID symptoms in patients who have substantially recovered, the calculus may be different — and the Complete Beginner's Guide to Home HBOT covers what to realistically expect from 1.3 ATA sessions.
The ViTAL5 Method™ for Post-COVID Recovery
The ViTAL5 Method™ — Post-COVID Recovery Stack
The ViTAL5 Method sequences five recovery modalities — including HBOT — for post-COVID and long COVID symptom management. The mitochondrial support protocol is specifically designed for the energy-generation failure that drives long COVID fatigue. The full sequencing guide is in the Starter Guide.
Get the ViTAL5 Starter Guide — $29The ViTAL5 Method™ brings together five complementary recovery modalities designed to work synergistically. For post-COVID recovery, the interactions between these modalities are particularly relevant to the overlapping mechanisms driving long COVID symptoms.
Mitochondrial Nutrition Protocol
Mitochondrial dysfunction is a central driver of long COVID fatigue and post-exertional malaise. The ViTAL5 nutrition protocol targets mitochondrial function directly through specific micronutrient timing and supplementation: CoQ10 (essential for electron transport chain function), B vitamins (cofactors for mitochondrial enzyme reactions), magnesium (required for ATP synthesis), and NAD+ precursors (critical for mitochondrial redox reactions). HBOT stimulates mitochondrial biogenesis — the creation of new mitochondria — but only if the raw materials for mitochondrial function are available. The nutrition protocol ensures those materials are present at the time of maximum HBOT-induced mitochondrial activation. This isn't supplementation for its own sake; it's timing nutritional substrate delivery to coincide with the biological window that HBOT opens.
Red Light Therapy for Neural Recovery
Near-infrared light (810–850nm) penetrates the skull and has documented effects on neuroinflammation and mitochondrial function in brain tissue — the exact mechanisms implicated in long COVID brain fog. The combination of HBOT (addressing cerebral hypoperfusion and neuroinflammation at the vascular level) with near-infrared light (directly activating mitochondrial function in neurons via cytochrome c oxidase) creates a multi-mechanism approach to the same problem. Applied within 60–90 minutes post-HBOT session, near-infrared light extends the mitochondrial activation window that HBOT opened. For long COVID patients with cognitive symptoms, this combination addresses the problem from two complementary biological angles.
Sleep Optimization as a Recovery Pillar
Sleep disturbance is both a symptom of long COVID and a driver of its perpetuation — poor sleep impairs immune regulation, increases neuroinflammation, and blocks the nocturnal tissue repair processes that depend on growth hormone. The ViTAL5 sleep protocol goes beyond generic sleep hygiene advice: it provides specific timing recommendations for HBOT relative to sleep (morning or early afternoon sessions to avoid circadian disruption), temperature protocols for sleep onset, and light management to support the altered circadian rhythms many long COVID patients experience. Treating sleep as an active intervention rather than a passive backdrop is particularly relevant to long COVID, where improving sleep quality can create a positive feedback loop that accelerates recovery from other symptoms.
Movement Protocol: Pacing for Post-Exertional Malaise
Standard exercise recommendations for most conditions involve progressive overload — gradually increasing intensity to drive adaptation. For long COVID patients with post-exertional malaise, this approach is actively harmful: pushing through fatigue triggers symptom crashes that can last days and potentially perpetuate the underlying pathology. The ViTAL5 movement protocol uses heart rate-based pacing — staying within the aerobic threshold (typically 60–70% of heart rate maximum for long COVID patients) — to maintain circulation and lymphatic flow without triggering the anaerobic threshold where post-exertional malaise is provoked. As mitochondrial function improves with HBOT and the nutrition protocol, the pacing threshold naturally rises — the protocol adjusts accordingly.
Getting Started: Finding a Long COVID HBOT Program
If you're considering clinical HBOT for long COVID, navigating the healthcare system to find an appropriate program requires some preparation.
Who Offers HBOT for Long COVID
Not all hyperbaric facilities offer HBOT for long COVID. Traditional wound care centers with hyperbaric units primarily treat FDA-cleared wound indications and may not have physicians experienced with long COVID protocols. Look for:
- Hyperbaric medicine specialists — board-certified physicians (ABPM or UHMS diplomates) with experience in neurological and off-label HBOT applications
- Long COVID clinics — academic medical centers and specialty long COVID programs have increasingly added HBOT as an option, sometimes as part of research protocols
- Integrative medicine practices — some functional medicine and integrative practices offer clinical HBOT under physician supervision, though quality varies significantly
Questions to Ask a Potential HBOT Provider for Long COVID
- What pressure and duration protocol do you use for long COVID? (Look for 2.0–2.4 ATA, 90 minutes, 20–40 sessions)
- Have you treated long COVID patients before? What outcomes have you seen?
- Will you coordinate with my primary care or long COVID specialist?
- Do you offer any assessment tools (cognitive testing, fatigue questionnaires) to track response?
- What is your cancellation or modification policy if I have a symptom flare during the protocol?
Insurance and Cost Realities
Long COVID is not an FDA-cleared indication for HBOT, which means insurance coverage is typically not available for this specific use. The cost of a 40-session clinical protocol at $150–$350 per session adds up to $6,000–$14,000 — a substantial out-of-pocket expense. Some providers offer self-pay rates significantly below standard billing rates; it's worth asking directly. Academic medical center research protocols sometimes offer HBOT as part of a funded study, which can reduce or eliminate patient cost — checking ClinicalTrials.gov for active long COVID HBOT studies in your region is worth doing before pursuing private-pay options.
Get the Free HBOT Long COVID Recovery Protocol Guide
Session structure, mitochondrial support protocols, pacing strategies, and the full research breakdown on HBOT for post-COVID recovery — in one guide.
Frequently Asked Questions
The evidence is promising and more rigorous than most long COVID treatments. The Zilberman-Itskovich 2022 RCT — double-blind, sham-controlled, 73 patients at 2.0 ATA — showed statistically significant improvements in cognitive function, fatigue, sleep quality, and pain, with supporting MRI perfusion data showing objective improvement in brain blood flow. A Belgian pilot study independently confirmed significant fatigue reduction. HBOT is not an FDA-cleared indication for long COVID, and it is not a cure. But the level of controlled trial evidence supporting it exceeds that for most other long COVID interventions currently being tried. Multiple larger trials are underway and results are expected in 2026.
The Zilberman-Itskovich 2022 RCT documented significant improvements in four symptom clusters: cognitive function (attention, memory, executive function on neuropsychological testing), fatigue (validated questionnaire scores), sleep quality, and pain. Brain imaging confirmed objective improvement in cerebral perfusion — not just subjective symptom reporting. Breathlessness and post-exertional malaise are reported to improve in observational data, but dedicated RCT evidence for these symptoms specifically is thinner. HBOT addresses multiple symptom clusters simultaneously because the underlying mechanisms — tissue microhypoxia, neuroinflammation, mitochondrial dysfunction — drive symptoms across all domains.
The evidence-based protocol from the Zilberman-Itskovich RCT: 40 sessions at 2.0 ATA, 90 minutes per session, 5 days per week for 8 weeks. The Belgian pilot used 10 sessions at 2.5 ATA. Current clinical practice typically uses 20–40 sessions at 2.0–2.4 ATA. Response varies — some patients report meaningful improvement within the first 10–20 sessions; others need the full 40-session course. Clinical assessment throughout the protocol determines when additional sessions are warranted. The 40-session, 8-week protocol is the template most hyperbaric physicians use when recommending HBOT for long COVID.
Home soft-shell chambers at 1.3 ATA are not a substitute for clinical HBOT for long COVID. The clinical trials used 2.0–2.5 ATA — pressures home chambers cannot reach — and it's unclear whether 1.3 ATA produces sufficient biological effect to replicate those outcomes. For long COVID with significant cognitive, fatigue, or other symptoms, clinical HBOT under physician supervision at 2.0+ ATA is what the evidence supports. Home chambers may serve as: a supportive adjunct between clinical sessions, a lower-intensity option for mild residual post-COVID symptoms in patients who have largely recovered, or part of a broader recovery stack alongside other interventions. They are not an evidence-based standalone treatment for moderate or severe long COVID.
No — long COVID is not an FDA-cleared indication for HBOT. HBOT is used off-label for long COVID based on the emerging evidence, primarily the Zilberman-Itskovich 2022 RCT. "Off-label" does not mean unsupported — physicians regularly use treatments off-label when evidence and clinical judgment warrant it. The evidence for HBOT in long COVID is meaningfully stronger than for many other treatments currently being tried for this condition. Insurance typically does not cover HBOT for long COVID due to the lack of FDA clearance. Multiple larger trials ongoing in 2025–2026 may eventually support an FDA clearance pathway if results continue to be positive.
Long COVID (PASC — post-acute sequelae of SARS-CoV-2) is defined as symptoms persisting 4+ weeks post-infection without another explanation. It affects an estimated 65 million people worldwide. It's hard to treat because it involves multiple overlapping mechanisms simultaneously: microclotting and endothelial damage causing tissue hypoxia, neuroinflammation in the brain and peripheral nervous system, mitochondrial dysfunction reducing cellular energy production, immune dysregulation with persistent inflammatory activation, and autonomic nervous system disruption (POTS, dysautonomia). Most treatments address one mechanism at a time. HBOT is unusual in simultaneously targeting microhypoxia, neuroinflammation, and mitochondrial function — which is why its RCT results have been more promising than most single-mechanism approaches tried so far.
Continue Reading
New to HBOT? The Complete Beginner's Guide to Home HBOT covers the fundamentals — what a session feels like, how chambers work, and what to expect in your first month.
Long COVID's cognitive symptoms overlap significantly with TBI, stroke, and other neurological conditions where HBOT has its strongest evidence base. The Brain Health & Neurological Recovery guide covers Dr. Paul Harch, Dr. Shai Efrati, and the neuroplasticity and neuroinflammation mechanisms in depth.
The fatigue and pain in long COVID share mechanisms with fibromyalgia and other chronic pain conditions. The HBOT for Chronic Pain & Inflammation guide covers TNF-α and IL-6 suppression — the same inflammatory pathways driving long COVID symptoms.
The mitochondrial dysfunction driving long COVID fatigue overlaps with aging and longevity mechanisms. The HBOT Anti-Aging & Longevity guide covers Thom's stem cell mobilization research and mitochondrial restoration in detail.
For protocol details — how many sessions, what frequency, how to structure a course — the HBOT Protocol & Sessions Guide has comparison tables by condition including neurological and recovery applications. The HBOT Safety Guide covers contraindications and monitoring — relevant before starting any HBOT protocol. The Wound Healing guide covers HBOT's strongest FDA-cleared evidence base for comparison. For buying decisions when you're ready to consider home equipment, the Top 5 Home Chambers comparison and cost guide cover the options. For athletic performance applications, the HBOT for Athletes guide covers sports recovery protocols.